F2G and Shionogi's olorofim meets Phase 3 non-inferiority endpoint
F2G and Shionogi have reported positive topline results from the Phase 3 OASIS trial, showing that the investigational oral antifungal olorofim is non-inferior to AmBisome (liposomal amphotericin B) followed by standard of care in patients with invasive aspergillosis who cannot be treated with azole therapy.
The 225-patient randomised study, which enrolled adults across multiple countries, measured all-cause mortality at Day 42 as its primary endpoint. The olorofim arm recorded a mortality rate of 23.8%, compared with 24.3% in the AmBisome-led comparator arm, a difference of -0.5 percentage points with a 95% confidence interval of -13.1% to 10.8%. The non-inferiority margin was pre-specified at 20%, so the trial met its statistical threshold. No new safety signals were identified for olorofim during the study.
Safety profile stands out
Beyond the primary efficacy read-out, the adverse-event data attracted attention. Drug-related treatment-emergent adverse events occurred in 35.8% of olorofim patients, compared with 63.9% in the comparator arm. The release attributed much of this gap to higher rates of renal events in the AmBisome group, which is a well-characterised toxicity of liposomal amphotericin B in clinical practice. For clinicians managing already-fragile immunocompromised patients, a tolerability advantage of this magnitude may carry as much practical weight as the non-inferiority result itself.
Johan Maertens, Professor of Haematology at University Hospitals Leuven and the study's principal investigator, said: "The OASIS topline results add to the growing body of evidence supporting olorofim's therapeutic potential in a hard-to-treat population with limited antifungal options."
Olorofim belongs to the orotomide class, acting on dihydroorotate dehydrogenase in the fungal pyrimidine biosynthesis pathway, a target with no overlap with existing antifungal mechanisms. It is orally dosed, which distinguishes it from intravenous amphotericin formulations and broadens its potential use setting. If approved, F2G and Shionogi position it as the first novel-mechanism agent for invasive aspergillosis in more than two decades.
Regulatory path and market context
F2G holds commercial rights in North America and non-Shionogi territories; Shionogi will handle Europe and Asia. Submission to the FDA will be led by F2G, while Shionogi will file in European and Asian jurisdictions. Full pivotal data will be presented at a future medical congress before regulatory dossiers are finalised. Olorofim already holds two FDA Breakthrough Therapy Designations, orphan drug status in the US for invasive aspergillosis and several other mould infections, and orphan designation from the EMA. QIDP status in the US adds a five-year exclusivity extension on top of any standard protection.
The competitive landscape for azole-refractory aspergillosis is thin by design, which is part of what made olorofim's clinical programme viable. Gilead's AmBisome, which served as the comparator in OASIS, remains a mainstay second-line agent despite its renal liability. Isavuconazole and voriconazole cover the azole-sensitive segment. A number of academic and early-stage industry groups are investigating novel antifungal mechanisms, including glucan synthase inhibitors and novel polyenes, but none has reached late-stage pivotal evaluation for this specific indication. If olorofim secures approval, it would enter a narrow but high-value niche with limited near-term competition, though pricing and reimbursement negotiations in Europe are likely to be complex given the rare-disease framing.
Investors will be focused on the congress presentation date, the timing of regulatory submissions in both the US and Europe, and whether the full dataset, including subgroup analyses and quality-of-life measures, confirms the tolerability advantage suggested by the topline release.